Inhibition of YBX1 by miR-216a Suppresses Proliferation andInvasion of Diffuse Large B-Cell Lymphoma

Background: MicroRNAs (miRNAs) could be implicated in tumori genesis of diffuse large B-cell lymphoma (DLBCL). Aims: To determine the role of MiR-216a in DLBCL. Study Design: Cell culture study. Methods: Expression of miR-216a in DLBCL cells was examined byqRT-PCR. Cell counting kit-8, bromodeoxyuridine staining and tran swell assays were performed to evaluate role of miR-216a on DLBCLcell growth. Target gene of miR-216a was verified by luciferasereporter assay. Results: MiR-216a was dramatically reduced in DLBCL cells com pared to the normal B-cell line (P < .01). MiR-216a reduced theviability and retarded DLBCL cell proliferation. The invasion ofDLBCL was suppressed by miR-216a. Y box binding protein 1 (YBX1)was validated as a target of miR-216a. Its expression was reduced bymiR-216a mimic and enhanced by miR-216a inhibitor in DB andSU-DHL-10 cells. Knockdown of YBX1 reduced cell viability, prolif eration, and invasion of DB and SU-DHL-10 cells. Conclusion: MiR-216a exerted tumor-suppressive effects on DLBCLcells through inhibition of YBX1, providing a new strategy forDLBCL.

PDF

___

1. Cerchietti L, Leonard JP. Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematol Am Soc Hematol Educ Program. 2013;2013:591-595.
2. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417-1429. [CrossRef]
3. Yamaguchi H, Hirakawa T, Inokuchi K. Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. J Clin Exp Hematop. 2011;51(1):1- 5. [CrossRef]
4. Wight JC, Chong G, Grigg AP, Hawkes EA. Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Rev. 2018;32(5):400- 415. [CrossRef]
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233. [CrossRef]
6. Tan K, Ge Y, Tian J, Li S, Lian Z. miRNA-9 inhibits apoptosis and promotes proliferation in angiotensin II-induced human umbilical vein endothelial cells by targeting MDGA2. Rev Cardiovasc Med. 2019;20(2):101-108. [CrossRef]
7. Mazan-Mamczarz K, Gartenhaus RB. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leuk Res. 2013;37(11):1420- 1428. [CrossRef]
8. Ahmadvand M, Eskandari M, Pashaiefar H, et al. Over expression of circulating miR-155 predicts prognosis in diffuse large B-cell lymphoma. Leuk Res. 2018;70:45- 48. [CrossRef]
9. Wang H, Wang A, Hu Z, et al. A critical role of miR-144 in diffuse large B-cell lymphoma proliferation and invasion. Cancer Immunol Res. 2016;4(4):337-344. [CrossRef]
10. Zhang Y, Tang X, Shi M, Wen C, Shen B. MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun. 2017;483(2):816-822. [CrossRef]
11. Zhao J, Li L, Yang T. MiR-216a-3p suppresses the proliferation and invasion of cervical cancer through downregulation of ACTL6A-mediated YAP signaling. J Cell Physiol. 2020;235(12):9718-9728. [CrossRef]
12. Zhen Q, Gao LN, Wang RF, et al. LncRNA DANCR promotes lung cancer by sequestering miR-216a. Cancer Control. 2018;25(1):1073274818769849. [CrossRef]
13. Liu Y, Huo Y, Wang D, et al. MiR-216a-5p/hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect. Biochem Biophys Res Commun. 2018;501(4):885-892. [CrossRef]
14. Liang C, Ma Y, Yong L, et al. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma. Cancer Sci. 2019;110(1):166-179. [CrossRef]
15. Zhou LL, Xu WL, Qin RJ, et al. The nuclear localization of Y-box binding protein-1 correlates with P-glycoprotein expression in diffuse large B cell lymphoma. Zhonghua Bing Li Xue Za Zhi. 2007;36(5):329-330.
16. Hanzawa K, Momose S, Higashi M, et al. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leuk Lymphoma. 2010;51(11):2054-2062. [CrossRef]
17. Kato M, Wang L, Putta S, et al. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells. J Biol Chem. 2010;285(44):34004-34015. [CrossRef]
18. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142(5):732- 744. [CrossRef]
19. Caramuta S, Lee L, Ozata DM, et al. Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. Blood Cancer J. 2013;3:e152. [CrossRef]
20. Li L, Ma HQ. MicroRNA-216a inhibits the growth and metastasis of oral squamous cell carcinoma by targeting eukaryotic translation initiation factor 4B. Mol Med Rep. 2015;12(2):3156-3162. [CrossRef]
21. Horvilleur E, Sbarrato T, Hill K, et al. A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia. 2014;28(5):1092-1102. [CrossRef]
22. Feng Y, Zhong M, Zeng S, et al. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics. 2019;11(1):35-51. [CrossRef]
23. Zeng X, Liu Y, Zhu H, Chen D, Hu W. Downregulation of miR-216a-5p by long noncoding RNA PVT1 suppresses colorectal cancer progression via modulation of YBX1 expression. Cancer Manag Res. 2019;11:6981-6993. [CrossRef]
24. Lemma S, Karihtala P, Haapasaari KM, et al. Biological roles and prognostic values of the epithelial–mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology. 2013;62(2):326-333. [CrossRef]
25. Forterre A, Komuro H, Aminova S, Harada M. A comprehensive review of cancer microRNA therapeutic delivery strategies. Cancers. 2020;12(7):1852. [CrossRef]
26. Chen P, Quan J, Jin L, et al. miR-216a-5p acts as an oncogene in renal cell carcinoma. Exp Ther Med. 2018;15(4):4039-4046. [CrossRef]
27. Wang QA, Yang Y, Liang X. LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration. J Ovarian Res. 2020;13(1):37. [CrossRef]
28. Shen H, Xu W, Luo W, et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol. 2011;39(5):558-569. [CrossRef]
29. Xu W, Zhou L, Qin R, Tang H, Shen H. Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur J Haematol. 2009;83(4):313-319. [CrossRef]
30. Miao X, Wu Y, Wang Y, et al. Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. Exp Cell Res. 2016;346(2):157-166. [CrossRef]
31. Prabhu L, Hartley AV, Martin M, et al. Role of post-translational modification of the Y box binding protein 1 in human cancers. Genes Dis. 2015;2(3):240-246. [CrossRef]
32. Sandhu SK, Croce CM, Garzon R. Micro-RNA expression and function in lymphomas. Adv Hematol. 2011;2011:347137. [CrossRef]
33. Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell–like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res. 2011;17(24):7785-7795. [CrossRef]